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With the extensive rollout of comprehensive antiretroviral
therapy (ART) now accelerating in sub-Saharan Africa, the
epidemiology, treatment and clinical outcomes of AIDS-
associated malignancies is rapidly evolving. This expan-
sion, largely enabled by PEPFAR (President's Emergency
Plan for AIDS Relief) and the Global Fund to fight AIDS,
Tuberculosis and Malaria, is dramatically increasing
access to complicated medical interventions in individu-
als who would otherwise be unable to afford them. Atti-
tudes and expectations of patients and their care-providers
are fortunately moving away from the former paradigm of
"can't do this in Africa." Populace expectation of having
access to life-prolonging treatments is becoming the new
paradigm. AIDS has led the way in this paradigm shift but
a movement for concurrently reinforcing chemotherapy
of AIDS-related malignancies has also been empowered
by the massive ART rollout.
In this presentation, we highlight the changes that are
occurring in both the Medical Oncology Unit and in the
AIDS Treatment Center at Hôpital General, in Yaoundé,
Cameroon. Hôpital General is a typical state-run hospital
with limited resources and a difficult-to-manage number
of ill patients, including impressive numbers of patients
with AIDS and AIDS-associated malignancies. During a
12-month period, we systematically conducted HIV test-
ing of all 632 patients with a confirmed new malignancy;
52 (8.2%) were HIV-positive. Concurrent HIV prevalence
in the general population was ~5.5 percent. Of these 52
HIV-positive patients with a documented malignancy, 14
(27%) had Kaposi's sarcoma (KS), 8 (15.4%) lymphoma,
7 (13.5%) breast cancer, 3 (5.7%) oropharyngeal cancer,
2 (3.9%) ovarian cancer.
In a subsequent 12-month period, we identified 57 addi-
tional KS patients of whom 50 (88%) were HIV-positive.
Among KS-positive or HIV-positive patients who received
both anti-KS chemotherapy by protocol (doxyrubicin,
bleomycin, vincristine), and concurrent ART, the time to
quantifiable recovery was markedly shorter compared to
recovery times in patients who received only anti-KS
chemotherapy. These findings have prompted a change in
AIDS-associated malignancy management at our institu-
tion. These patients are now co-managed in the same
clinic by medical oncologists and experts in ART. With the
recent expanded access to ART we believe that this synergy
in case management will increase the quality and the
number of life years in this ever-expanding population.
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